FDA shared a post on LinkedIn : The FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which identifies bulk drug substances that outsourcing facilities may use in compounding when there is a clinical need
Semaglutide and tirzepatide work by mimicking hormones that regulate appetite and insulin signaling
Pancreatitis risk: There is a potential risk of pancreatitis associated with tirzepatide use
Compounded Semaglutide is an injectable GLP-1 prescription weight loss medication with the same active ingredient as Ozempic and Wegovy
doi:10.1016/j.drugalcdep.2018.06.038 154
However, if the redness spreads, becomes very painful, or is accompanied by a fever, you should contact a healthcare provider immediately